

## REMARKS

### I. Status of Claims

Claims 1-21 are pending in the present application. Claims 22, 23 and 24 have been cancelled. Support for the amendments to the Specification is found in the Specification as filed, since these amendments are purely formal in nature. Support for the amendments to claims 10, 16 and 21 is found in the claims themselves, since these amendments are purely formal in nature.


A hard copy and a CRF version of the Sequence Listing, as well as a statement that the two versions are the same, are being submitted herewith.

### II. Conclusions

If any fee is due in connection herewith not already accounted for, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-3575

  
John A. Lamerdin, Ph.D.  
Attorney for Applicants  
Reg. No. 44,858

Date: 4/8/04